ClinicalTrials.gg
CompletedNCT02981602Updated Aug 10, 2021Results posted

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

A Phase 2 interventional study of IONIS-HBVRx and Placebo in Hepatitis B and Chronic Hepatitis B Atypical, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
13th of 16
31 · median 103
Started
2017
the only one that year
Phase 2
7 of 16
1 open now
Registered
1st of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 1st registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection

Read the detailed description

This study examines the effects of IONIS-HBVRx or placebo (3:1 randomization) administered subcutaneously to treatment-naïve patients who are chronically infected with HBV and the effects of subsequent nucleos(t)ide analogue treatment on these patients.

03

Conditions studied

  • Hepatitis B
  • Chronic Hepatitis B Atypical

Keywords

  • Hepatitis
  • Chronic
  • HBV
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years
  • Chronic infection ≥6 months (e.g., positive for serum HBsAg ≥ 6 months)
  • Plasma HBV DNA ≥ 2 x 1000 IU/mL (HBV DNA adequately suppressed for exploratory nucleos(t)ide analogue experienced cohort)
  • Serum HBsAg ≥ 50 IU/mL
  • Exploratory nucleos(t)ide analogue experienced cohort only: currently taking and have been taking tenofovir or entecavir without changes in drug, dose level and/or frequency of administration for ≥ 12 months and expect to continue taking without change through to the end of their participation in this study

Exclusion criteria

Exclusion Criteria:

  • Current or prior receipt of anti- nucleos(t)ide analogue therapy. Patients who have failed prior interferon treatment, greater than 6 months prior to Screening, may be evaluated for possible participation in the study (not applicable for exploratory nucleos(t)ide analogue experienced cohort)
  • History of liver cirrhosis and/or evidence of cirrhosis as determined by any of the following:

    1. Liver (i.e., Metavir Score F4) within 2 years of Screening, or
    2. Fibroscan > 12 KPa, within 12 months of Screening, or
    3. -to- Index (APRI) > 2 and Fibrosure result > 0.7 within 12 months of Screening For patients without a test for cirrhosis in the above timeframes, Fibroscan, or APRI and Fibrosure, may be performed during the screening period to rule out cirrhosis
  • History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices
  • History of liver disease other than Hepatitis B
  • Co-infection with virus (HCV), (HIV), or hepatitis D virus (HDV)
  • > 35 kg/m2
  • History of, or suspected presence of vasculitis
  • Received solid organ or bone marrow transplant
  • Currently taking, or took within 3 months of Screening, any drugs (e.g., prednisone)
  • Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥ 200 ng/mL. If the screening alpha-fetoprotein is ≥ 50 ng/mL and \< 200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization
  • Clinically-significant abnormalities aside from chronic HBV infection in medical history (e.g., previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination
  • History of bleeding diathesis or coagulopathy
  • History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa)
  • History of excess alcohol consumption within 6 months of Screening
  • History of drug abuse or dependence, or recreational use of drugs: within 3 months of Screening for soft drugs (such as marijuana) and within 1-year of Screening for hard drugs (such as cocaine, phencyclidine [PCP])
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    IONIS-HBVRx

    Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection

    Drug: IONIS-HBVRx

  • Placebo comparator
    Placebo

    Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator

    Drug: Placebo

Interventions

  • Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection

    Also known as: ISIS 505358

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%)

    An adverse event is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Any adverse event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any important medical event according to medical judgment were categorized as SAE.

    Time frame: Up to Day 211

  2. Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Over Time

    Blood samples were collected for the analysis of clinical parameters including ALT, ALP, CK, GGT, LDH and AST. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  3. Change From Baseline in Clinical Chemistry Parameters : Albumin and Total Protein Over Time

    Blood samples were collected for the analysis of clinical chemistry parameter-albumin and total protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  4. Change From Baseline Values in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphate, Glucose, Blood Urea Nitrogen, Cholesterol and Urate

    Blood samples were collected for the analysis of clinical parameters including sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose, blood urea nitrogen (BUN), cholesterol and urate. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Outcome Measure Timeframe: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  5. Change From Baseline Values in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameters: direct bilirubin, total bilirubin, indirect bilirubin and creatinine. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  6. Change From Baseline for Hematology Parameters: Basophils, Eosinophils, White Blood Cells (WBC), Lymphocytes, Neutrophils, Monocytes, and Platelets

    Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, WBC, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  7. Change From Baseline for Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameters including hemoglobin at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  8. Change From Baseline for Hematology Parameter: Hematocrit

    Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  9. Change From Baseline Values in Urine Specific Gravity

    Urine samples were collected for the analysis of urine specific gravity. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value. Urine specific gravity is measured as the ratio of urine density compared with water density.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  10. Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio

    Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  11. Change From Baseline Values in Urine Protein

    Urine samples were collected for the analysis of urine protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  12. Change From Baseline Values in Blood Coagulation Factors: Activated Partial Thromboplastin Time and Prothrombin Time

    Blood samples were collected for the analysis of blood coagulation factors:activated partial thromboplastin time (aPTT) and Prothrombin Time (PT). Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211

  13. Change From Baseline Values in Blood Coagulation Factor: Prothrombin International Normalized Ratio

    Blood samples were collected for the analysis of blood coagulation factor: Prothrombin International normalized ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211

  14. Change in Complement C3 Level at Worst Case Post Baseline Relative to Baseline

    Blood samples were collected from participants to evaluate change in complement C3 level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C3 was the minimum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and up to Day 211

  15. Change in Complement C5a Level at Worst Case Post Baseline Relative to Baseline

    Blood samples were collected from participants to evaluate change in complement C5a level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C5a was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and up to Day 211

  16. Change in Complement Bb Level at Worst Case Post Baseline Relative to Baseline

    Blood samples were collected from participants to evaluate change in complement Bb level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement Bb was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and up to Day 211

  17. Number of Participants With Reported Pregnancy

    Female participants who were not surgically sterile or post-menopausal, underwent urine beta Human chorionic gonadotropin (Beta-HCG) pregnancy test.

    Time frame: Up to Day 211

  18. Change From Baseline in Body Temperature

    Body temperature was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  19. Change From Baseline in Body Weight

    Body weight was measured at indicated time points. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 211

  20. Change From Baseline in Diastolic Blood Pressure and Systolic Blood Pressure

    Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  21. Change From Baseline in Respiratory Rate

    Respiratory Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  22. Change From Baseline in Pulse Rate

    Pulse Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211

  23. Number of Participants With Abnormal Findings in Physical Examination

    Physical examinations included assessment of the dermatologic, cardiovascular, respiratory, gastrointestinal, and neurological systems.

    Time frame: Up to Day 211

  24. Number of Participants Who Received Atleast One Concomitant Medication

    A concomitant medication is defined as any medication initiated after the first dose of study, or initiated prior to the first dose of study drug and continued after the first dose of study drug.

    Time frame: Up to Day 211

  25. Change From Baseline in Electrocardiogram Mean Ventricular Rate

    Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured mean ventricular rate (VR). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113

  26. Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia Interval and QTc Corrected by Bazett's Formula

    Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured QRS duration, uncorrected QT interval, QT corrected interval-Fredericia \[QTcF\] interval and QTc corrected by Bazett's formula (QTcB). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113

Secondary outcomes

  1. Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29

    Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The last observation carried forward (LOCF) method was used to impute missing values at Day 29 in this analysis.

    Time frame: Baseline (Day 1 pre-dose) and Day 29

  2. Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31

    Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Week 31

  3. Change From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29

    Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The LOCF method was used to impute missing values at Day 29 in this analysis.

    Time frame: Baseline (Day 1 pre-dose) and Day 29

  4. Change From Baseline in HBsAg Level in Serum at Week 31

    Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1 pre-dose) and Week 31

  5. Percentage of Participants Who Achieved HBsAg Loss at Day 29 and Week 31

    Blood samples were collected to evaluate the percentage of participants with HBsAg loss at Day 29 and Week 31. A 'Loss' of HBsAg means antigen is negative. HBsAg Loss percentage is defined as number of participants with HBsAg loss divided by total number of participants assessed multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug.

    Time frame: At Day 29 and Week 31

  6. Percentage of Participants Who Achieved HBV e Antigen (HBeAg) Loss at Day 29 and Week 31 Who Were HBeAg Positive at Baseline

    Blood samples were collected to evaluate the percentage of participants with HBeAg loss at Day 29 and Week 31. A 'Loss' of HBeAg means antigen is negative. HBeAg Loss percentage is defined as number of participants with HBeAg loss divided by number of participants with positive HBeAg at Baseline multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug. Participants was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.

    Time frame: Baseline (Day 1, Pre dose) and at Day 29 and Week 31

  7. Change From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline

    Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 International Units/milliliter (IU/mL).

    Time frame: Baseline (Day 1, Pre dose) and at Day 29

  8. Change From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline

    Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.

    Time frame: Baseline (Day 1, Pre dose) and Week 31

  9. Plasma Concentrations of GSK3228836 in Participants With Chronic HBV Infection

    Plasma samples were collected from participants with chronic HBV infection at indicated time points for pharmacokinetic analysis of GSK3228836.

    Time frame: Day 1:pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, Days 2 and 23: 24 hours post-dose, Day 4: 72 hours post-dose, Days 8 and 15: pre-dose, Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, and Days 29, 36, 57, 85, 113, and 211

07

Results

Posted Dec 21, 2020

Participant flow

This study evaluated safety, tolerability, pharmacokinetics and antiviral activity of GSK3228836 in two population of participants with Chronic Hepatitis B (CHB) virus infection: treatment-naive participants (Cohorts 1, 2 and 3) and participants on stable nucleos(t)ide treatment (Cohort 4)

Participant flow — Overall Study
MilestoneCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Started612652
Completed612642
Not completed00010
Withdrew: Adverse event00010

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%)

An adverse event is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Any adverse event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any important medical event according to medical judgment were categorized as SAE.

Time frame:
Up to Day 211
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%)
ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Non-SAE (>=5%)56230
SAE01000
PrimaryChange From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Over Time

Blood samples were collected for the analysis of clinical parameters including ALT, ALP, CK, GGT, LDH and AST. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Over Time
Units per liter (U/L)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
ALT, Day29, n= 6,12,6,4,215.7 ± 56.6552.5 ± 112.14-0.7 ± 8.9145.3 ± 32.10-0.5 ± 3.54
ALT, Day57, n= 5,12,6,4,245.6 ± 60.0637.5 ± 58.31-2.2 ± 8.7746.0 ± 42.311.0 ± 3.54
ALT, Day85, n= 6,12,6,4,2-10.5 ± 30.208.8 ± 29.870.5 ± 9.147.5 ± 13.18-0.5 ± 0.71
ALT, Day211, n= 6,12,6,4,2-24.3 ± 43.68-16.2 ± 30.75-3.2 ± 12.886.5 ± 9.955.5 ± 3.54
ALP, Day29, n= 6,12,6,4,2-3.2 ± 8.235.2 ± 14.60-0.7 ± 8.129.8 ± 11.950.0 ± 0.90
ALP, Day57, n= 5,12,6,4,27.8 ± 12.0913.3 ± 14.558.0 ± 11.311.3 ± 9.224.0 ± 5.66
ALP, Day85, n= 6,12,6,4,27.2 ± 7.739.9 ± 9.247.7 ± 9.890.0 ± 4.246.0 ± 4.24
ALP, Day211, n= 6,12,6,4,218.2 ± 10.3211.3 ± 13.619.3 ± 8.711.5 ± 7.855.0 ± 11.31
AST, Day29, n= 6,12,6,4,217.7 ± 50.4131.0 ± 78.95-0.5 ± 3.9927.5 ± 23.072.0 ± 1.41
AST, Day57, n= 5,12,6,4,222.8 ± 34.3023.3 ± 50.252.3 ± 3.3318.3 ± 15.844.5 ± 2.12
AST, Day85, n= 6,12,6,4,23.0 ± 16.664.6 ± 20.371.5 ± 4.465.5 ± 4.513.0 ± 0.00
AST, Day211, n= 6,12,6,4,2-9.3 ± 22.20-6.5 ± 16.463.8 ± 3.765.3 ± 3.304.5 ± 2.12
CK, Day29, n= 6,12,6,4,235.5 ± 127.87-17.6 ± 28.46-13.2 ± 29.36-6.8 ± 19.2149.0 ± 62.23
CK, Day57, n= 5,12,6,4,2-9.6 ± 47.779.8 ± 25.89-0.5 ± 24.0457.0 ± 142.54111.0 ± 148.49
CK, Day85, n= 6,12,6,4,226.2 ± 61.6416.8 ± 28.515.0 ± 49.78178.8 ± 359.3826.5 ± 31.82
CK, Day211, n= 6,12,6,4,229.2 ± 71.0424.2 ± 42.3977.2 ± 132.5953.8 ± 50.6894.0 ± 114.55
GGT, Day29, n= 6,12,6,4,2-2.3 ± 3.883.1 ± 8.27-11.7 ± 22.275.3 ± 6.70-2.5 ± 2.12
GGT, Day57, n= 5,12,6,4,21.4 ± 3.446.5 ± 15.85-17.0 ± 36.309.0 ± 3.742.0 ± 2.83
GGT, Day85, n= 6,12,6,4,2-0.5 ± 1.523.2 ± 6.66-17.5 ± 37.565.3 ± 3.101.0 ± 2.83
GGT, Day211, n= 6,12,6,4,2-7.7 ± 11.57-1.1 ± 2.15-17.8 ± 41.064.3 ± 2.222.0 ± 1.41
LDH, Day29, n= 6,12,6,4,212.0 ± 27.031.7 ± 41.09-1.5 ± 15.0046.8 ± 35.5112.5 ± 0.71
LDH, Day57, n= 5,12,6,4,24.4 ± 26.68-4.7 ± 21.4022.0 ± 36.744.8 ± 9.2511.0 ± 11.31
LDH, Day85, n= 6,12,6,4,29.5 ± 22.79-12.3 ± 22.4229.2 ± 35.293.8 ± 17.196.0 ± 8.49
LDH, Day211, n= 6,12,6,4,27.0 ± 18.783.3 ± 28.0655.0 ± 54.5925.3 ± 13.6024.0 ± 22.63
PrimaryChange From Baseline in Clinical Chemistry Parameters : Albumin and Total Protein Over Time

Blood samples were collected for the analysis of clinical chemistry parameter-albumin and total protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Grams per liter
Change From Baseline in Clinical Chemistry Parameters : Albumin and Total Protein Over Time
Grams per literCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Albumin, Day29, n= 6,12,6,4,2-0.8 ± 1.470.3 ± 2.23-1.3 ± 1.513.0 ± 2.161.5 ± 3.54
Albumin, Day57, n= 5,12,6,4,20.6 ± 1.671.7 ± 2.570.0 ± 1.551.8 ± 1.505.5 ± 0.71
Albumin, Day85, n= 6,12,6,4,20.0 ± 2.002.0 ± 3.28-0.8 ± 3.191.3 ± 2.223.0 ± 2.83
Albumin, Day211, n= 6,12,6,4,21.0 ± 2.283.3 ± 2.260.7 ± 3.014.3 ± 0.503.0 ± 5.66
Total Protein, Day29, n= 6,12,6,4,2-1.8 ± 2.641.9 ± 3.18-1.8 ± 4.756.5 ± 3.111.5 ± 7.78
Total Protein, Day57, n= 5,12,6,4,20.8 ± 3.493.8 ± 4.270.2 ± 3.253.0 ± 1.416.0 ± 0.0
Total Protein, Day85, n= 6,12,6,4,20.8 ± 3.543.3 ± 5.030.3 ± 4.973.5 ± 3.424.5 ± 2.12
Total Protein, Day211, n= 6,12,6,4,22.5 ± 4.815.1 ± 4.231.7 ± 3.338.0 ± 2.714.5 ± 12.02
PrimaryChange From Baseline Values in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphate, Glucose, Blood Urea Nitrogen, Cholesterol and Urate

Blood samples were collected for the analysis of clinical parameters including sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose, blood urea nitrogen (BUN), cholesterol and urate. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Outcome Measure Timeframe: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Millimoles per liter
Change From Baseline Values in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphate, Glucose, Blood Urea Nitrogen, Cholesterol and Urate
Millimoles per literCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Bicarbonate, Day29, n= 6,12,6,4,20.3 ± 1.210.2 ± 1.111.0 ± 1.410.0 ± 2.16-2.0 ± 2.83
Bicarbonate, Day57, n= 5,12,6,4,21.0 ± 2.65-0.1 ± 2.02-0.2 ± 2.140.3 ± 2.87-3.0 ± 2.83
Bicarbonate, Day85, n= 6,12,6,4,20.2 ± 3.920.5 ± 1.83-0.8 ± 0.75-0.8 ± 0.50-2.0 ± 2.83
Bicarbonate, Day211, n= 6,12,6,4,22.8 ± 1.94-1.0 ± 1.81-0.8 ± 1.72-0.8 ± 2.22-2.0 ± 4.24
Calcium, Day29, n= 6,12,6,4,20.012 ± 0.08110.015 ± 0.0735-0.040 ± 0.05060.063 ± 0.0479-0.030 ± 0.0707
Calcium, Day57, n= 5,12,6,4,20.036 ± 0.06580.029 ± 0.0899-0.038 ± 0.04710.013 ± 0.01500.010 ± 0.0566
Calcium, Day85, n= 6,12,6,4,20.020 ± 0.06720.046 ± 0.0944-0.028 ± 0.0679-0.013 ± 0.06750.050 ± 0.0707
Calcium, Day211, n= 6,12,6,4,20.052 ± 0.06180.056 ± 0.0745-0.025 ± 0.07890.068 ± 0.0746-0.025 ± 0.1344
Chloride, Day29, n= 6,12,6,4,2-0.8 ± 2.14-0.3 ± 1.970.8 ± 1.94-2.0 ± 1.83-1.5 ± 0.71
Chloride, Day57, n= 5,12,6,4,2-1.2 ± 2.170.0 ± 1.860.7 ± 0.82-1.0 ± 0.00-1.5 ± 0.71
Chloride, Day85, n= 6,12,6,4,2-1.0 ± 2.370.8 ± 1.851.5 ± 1.64-0.3 ± 1.50-1.5 ± 2.12
Chloride, Day211, n= 6,12,6,4,2-0.8 ± 2.480.0 ± 2.301.7 ± 2.94-0.5 ± 0.58-1.0 ± 1.41
Cholesterol, Day29, n= 6,12,6,4,2-0.027 ± 0.2281-0.129 ± 0.4305-0.252 ± 0.20440.123 ± 0.9238-0.155 ± 0.7000
Cholesterol, Day57, n= 5,12,6,4,2-0.422 ± 0.3739-0.328 ± 0.8109-0.717 ± 0.52160.480 ± 0.72780.815 ± 0.5303
Cholesterol, Day85, n= 6,12,6,4,2-0.380 ± 0.5772-0.211 ± 0.8659-0.812 ± 0.27040.195 ± 0.50730.390 ± 0.5091
Cholesterol, Day211, n= 6,12,6,4,2-0.110 ± 0.4369-0.121 ± 0.7581-0.423 ± 0.69800.960 ± 0.39820.360 ± 0.7354
Glucose, Day29, n= 6,12,6,4,20.170 ± 0.71480.009 ± 0.77820.498 ± 1.3437-0.290 ± 0.12990.225 ± 0.0778
Glucose, Day57, n= 5,12,6,4,20.056 ± 0.4161-0.110 ± 1.0510-0.157 ± 0.51470.415 ± 1.4055-0.360 ± 0.1980
Glucose, Day85, n= 6,12,6,4,20.018 ± 0.3725-0.218 ± 1.0970-0.315 ± 0.29590.073 ± 0.4524-0.110 ± 0.0000
Glucose, Day211, n= 6,12,6,4,20.093 ± 0.4956-0.205 ± 1.0796-0.223 ± 0.5205-0.373 ± 0.6375-0.110 ± 0.3111
Magnesium, Day29, n= 6,12,6,4,2-0.008 ± 0.03760.013 ± 0.0377-0.025 ± 0.05240.000 ± 0.00000.025 ± 0.0354
Magnesium, Day57, n= 5,12,6,4,20.000 ± 0.05000.038 ± 0.0483-0.033 ± 0.05160.013 ± 0.04790.000 ± 0.0000
Magnesium, Day85, n= 6,12,6,4,2-0.025 ± 0.06120.029 ± 0.0620-0.033 ± 0.0606-0.038 ± 0.04790.000 ± 0.0000
Magnesium, Day211, n= 6,12,6,4,20.008 ± 0.05850.042 ± 0.0669-0.008 ± 0.04920.050 ± 0.05770.025 ± 0.0354
Phosphate, Day29, n= 6,12,6,4,20.052 ± 0.1488-0.010 ± 0.11230.023 ± 0.1472-0.073 ± 0.0562-0.050 ± 0.1131
Phosphate, Day57, n= 5,12,6,4,20.052 ± 0.1657-0.064 ± 0.1072-0.025 ± 0.1088-0.058 ± 0.1250-0.020 ± 0.1556
Phosphate, Day85, n= 6,12,6,4,2-0.020 ± 0.1942-0.003 ± 0.13420.055 ± 0.1001-0.008 ± 0.20170.080 ± 0.2546
Phosphate, Day211, n= 6,12,6,4,20.023 ± 0.05280.056 ± 0.18000.005 ± 0.1401-0.018 ± 0.1231-0.130 ± 0.1273
Potassium, Day29, n= 6,12,6,4,20.08 ± 0.2480.16 ± 0.2150.12 ± 0.458-0.05 ± 0.2890.00 ± 0.141
Potassium, Day57, n= 5,12,6,4,20.08 ± 0.3350.27 ± 0.1610.08 ± 0.2930.03 ± 0.206-0.05 ± 0.354
Potassium, Day85, n= 6,12,6,4,20.07 ± 0.1510.37 ± 0.1830.20 ± 0.2100.00 ± 0.4760.00 ± 0.566
Potassium, Day211, n= 6,12,6,4,20.03 ± 0.3670.31 ± 0.2840.30 ± 0.2280.23 ± 0.2990.05 ± 0.919
Sodium, Day29, n= 6,12,6,4,20.2 ± 0.750.2 ± 2.330.7 ± 2.42-1.0 ± 2.16-1.5 ± 0.71
Sodium, Day57, n= 5,12,6,4,2-1.0 ± 1.87-0.2 ± 2.21-0.2 ± 1.47-0.5 ± 1.29-1.0 ± 0.00
Sodium, Day85, n= 6,12,6,4,2-0.3 ± 2.160.5 ± 2.280.2 ± 1.72-0.8 ± 1.71-2.0 ± 1.41
Sodium, Day211, n= 6,12,6,4,2-0.5 ± 2.35-0.3 ± 1.960.2 ± 1.940.3 ± 0.50-1.0 ± 0.00
Urate, Day29, n= 6,12,6,4,20.0310 ± 0.050070.0248 ± 0.04039-0.0127 ± 0.01127-0.0060 ± 0.027280.0355 ± 0.04172
Urate, Day57, n= 5,12,6,4,20.0192 ± 0.037130.0119 ± 0.05856-0.0158 ± 0.02260-0.0043 ± 0.043770.0030 ± 0.00424
Urate, Day85, n= 6,12,6,4,20.0168 ± 0.04298-0.0061 ± 0.04391-0.0100 ± 0.02592-0.0078 ± 0.049840.0440 ± 0.02121
Urate, Day211, n= 6,12,6,4,20.0012 ± 0.03783-0.0005 ± 0.05949-0.0128 ± 0.040860.0370 ± 0.025990.0325 ± 0.02899
BUN, Day29, n= 6,12,6,4,20.417 ± 1.01920.356 ± 0.50400.415 ± 0.61250.180 ± 0.89800.355 ± 1.0112
BUN, Day57, n= 5,12,6,4,20.788 ± 0.99030.238 ± 0.79600.535 ± 1.14510.980 ± 1.55430.180 ± 0.2546
BUN, Day85, n= 6,12,6,4,2-0.177 ± 0.9241-0.059 ± 0.89740.833 ± 0.70110.000 ± 1.20400.000 ± 0.5091
BUN, Day211, n= 6,12,6,4,20.358 ± 1.2580-0.208 ± 1.09410.713 ± 1.15100.893 ± 1.44630.000 ± 0.0000
PrimaryChange From Baseline Values in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameters: direct bilirubin, total bilirubin, indirect bilirubin and creatinine. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Micromoles per liter
Change From Baseline Values in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, and Creatinine
Micromoles per literCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Total Bilirubin, Day29, n= 6,12,6,4,2-1.72 ± 2.699-1.07 ± 2.529-1.92 ± 2.497-1.53 ± 3.4971.40 ± 1.414
Total Bilirubin, Day57, n= 5,12,6,4,2-2.14 ± 2.105-0.40 ± 3.930-1.72 ± 1.216-0.33 ± 3.8023.85 ± 6.576
Total Bilirubin, Day85, n= 6,12,6,4,2-1.47 ± 2.151-0.78 ± 2.840-1.52 ± 3.411-0.78 ± 2.2905.40 ± 7.071
Total Bilirubin, Day211, n= 6,12,6,4,2-0.87 ± 2.608-0.87 ± 3.5380.40 ± 5.9071.00 ± 2.4322.75 ± 4.738
Direct Bilirubin, Day29, n= 6,12,6,4,20.00 ± 0.000-0.02 ± 0.0610.02 ± 0.0410.00 ± 0.0000.00 ± 0.000
Direct Bilirubin, Day57, n= 5,12,6,4,20.00 ± 0.000-0.02 ± 0.061-0.07 ± 0.1670.05 ± 0.1050.00 ± 0.000
Direct Bilirubin, Day85, n= 6,12,6,4,20.00 ± 0.000-0.02 ± 0.061-0.07 ± 0.1670.00 ± 0.0000.00 ± 0.000
Direct Bilirubin, Day211, n= 6,12,6,4,20.00 ± 0.000-0.02 ± 0.0610.05 ± 0.1220.00 ± 0.0000.00 ± 0.000
Indirect Bilirubin, Day29, n= 0,0,1,0,0——-0.60 ± NA——
Indirect Bilirubin, Day211, n= 0,0,1,0,0——10.50 ± NA——
Creatinine, Day29, n= 6,12,6,4,23.8 ± 3.397.8 ± 4.37-0.3 ± 7.008.8 ± 5.892.3 ± 3.18
Creatinine, Day57, n= 5,12,6,4,22.7 ± 5.135.5 ± 6.532.5 ± 5.082.3 ± 12.182.3 ± 9.55
Creatinine, Day85, n= 6,12,6,4,20.8 ± 8.733.9 ± 6.461.0 ± 5.672.0 ± 5.432.3 ± 3.18
Creatinine, Day211, n= 6,12,6,4,20.8 ± 6.624.0 ± 8.824.0 ± 6.822.0 ± 5.436.8 ± 3.18
PrimaryChange From Baseline for Hematology Parameters: Basophils, Eosinophils, White Blood Cells (WBC), Lymphocytes, Neutrophils, Monocytes, and Platelets

Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, WBC, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · 10^9 cells per liters
Change From Baseline for Hematology Parameters: Basophils, Eosinophils, White Blood Cells (WBC), Lymphocytes, Neutrophils, Monocytes, and Platelets
10^9 cells per litersCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Basophils, Day 290.00 ± 0.0000.01 ± 0.0290.00 ± 0.0000.0 ± 0.000.0 ± 0.00
Basophils, Day 570.00 ± 0.0000.00 ± 0.0000.00 ± 0.0000.0 ± 0.000.0 ± 0.00
Basophils, Day 85-0.02 ± 0.0410.00 ± 0.0000.00 ± 0.0000.0 ± 0.000.0 ± 0.00
Basophils, Day 2110.00 ± 0.0000.01 ± 0.0290.00 ± 0.0000.0 ± 0.000.0 ± 0.00
Eosinophils, Day 290.03 ± 0.103-0.02 ± 0.1030.03 ± 0.0520.00 ± 0.0820.00 ± 0.000
Eosinophils, Day 57-0.02 ± 0.098-0.03 ± 0.1150.05 ± 0.0840.00 ± 0.082-0.10 ± 0.000
Eosinophils, Day 850.08 ± 0.172-0.03 ± 0.1150.02 ± 0.075-0.03 ± 0.126-0.05 ± 0.071
Eosinophils, Day 2110.10 ± 0.110-0.04 ± 0.1080.03 ± 0.0520.05 ± 0.0580.05 ± 0.071
WBC, Day 29-0.18 ± 1.206-0.60 ± 0.921-0.12 ± 0.8260.28 ± 0.624-1.15 ± 0.212
WBC, Day 57-0.33 ± 1.172-0.49 ± 0.958-0.37 ± 1.2040.08 ± 0.222-0.95 ± 0.636
WBC, Day 85-0.58 ± 1.177-0.63 ± 0.796-0.65 ± 0.8140.43 ± 0.556-1.05 ± 0.071
WBC, Day 211-0.45 ± 1.0670.01 ± 0.6960.10 ± 1.8340.70 ± 0.589-0.85 ± 0.212
Lymphocytes, Day 29-0.10 ± 0.219-0.27 ± 0.293-0.03 ± 0.294-0.10 ± 0.2160.20 ± 0.283
Lymphocytes Day 570.00 ± 0.200-0.15 ± 0.275-0.10 ± 0.456-0.05 ± 0.100-0.05 ± 0.071
Lymphocytes, Day 850.17 ± 0.288-0.13 ± 0.273-0.03 ± 0.2580.10 ± 0.294-0.10 ± 0.000
Lymphocytes, Day 2110.17 ± 0.301-0.11 ± 0.334-0.07 ± 0.2340.15 ± 0.208-0.10 ± 0.141
Neutrophils, Day 29-0.17 ± 1.027-0.36 ± 0.945-0.17 ± 0.7060.30 ± 0.392-1.05 ± 0.212
Neutrophils, Day 57-0.30 ± 1.075-0.31 ± 0.898-0.32 ± 1.3010.13 ± 0.275-0.60 ± 0.849
Neutrophils, Day 85-0.95 ± 0.812-0.45 ± 1.026-0.67 ± 0.5850.35 ± 0.342-0.65 ± 0.212
Neutrophils, Day 211-0.75 ± 0.8730.18 ± 0.7250.08 ± 1.9670.48 ± 0.377-0.55 ± 0.212
Monocytes, Day 290.08 ± 0.117-0.01 ± 0.1380.02 ± 0.0980.08 ± 0.050-0.25 ± 0.212
Monocytes, Day 570.00 ± 0.089-0.01 ± 0.1310.00 ± 0.1670.03 ± 0.096-0.15 ± 0.354
Monocytes, Day 850.08 ± 0.075-0.04 ± 0.1240.03 ± 0.0820.03 ± 0.050-0.20 ± 0.283
Monocytes, Day 2110.07 ± 0.103-0.05 ± 0.1000.02 ± 0.0750.10 ± 0.115-0.15 ± 0.212
Platelets, Day 29-0.5 ± 23.87-8.3 ± 17.2311.0 ± 21.9418.0 ± 32.2816.0 ± 9.90
Platelets, Day 57-2.5 ± 26.76-8.3 ± 31.779.7 ± 37.08-7.5 ± 8.7024.5 ± 17.68
Platelets, Day 85-5.2 ± 31.92-8.3 ± 29.5922.2 ± 27.951.5 ± 7.1414.5 ± 40.31
Platelets, Day 21112.3 ± 22.814.6 ± 43.1525.8 ± 20.4917.3 ± 20.52-4.5 ± 44.55
PrimaryChange From Baseline for Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameters including hemoglobin at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Grams per liter
Change From Baseline for Hematology Parameters: Hemoglobin
Grams per literCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-7.3 ± 3.50-6.8 ± 8.74-11.3 ± 7.31-6.0 ± 6.48-11.5 ± 2.12
Day 57-3.3 ± 10.25-3.0 ± 10.79-5.8 ± 9.28-3.8 ± 6.95-3.5 ± 4.95
Day 85-4.0 ± 10.60-4.8 ± 13.13-9.2 ± 10.07-0.3 ± 3.86-5.0 ± 9.90
Day 211-0.7 ± 15.731.8 ± 16.68-7.5 ± 6.474.8 ± 5.190.0 ± 1.41
PrimaryChange From Baseline for Hematology Parameter: Hematocrit

Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Percentage of red blood cells in blood
Change From Baseline for Hematology Parameter: Hematocrit
Percentage of red blood cells in bloodCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-2.47 ± 1.150-2.39 ± 2.858-4.20 ± 2.577-2.23 ± 2.089-3.30 ± 0.283
Day 57-1.17 ± 2.630-1.04 ± 3.089-2.17 ± 3.080-1.10 ± 2.482-0.80 ± 2.546
Day 85-1.33 ± 3.043-0.98 ± 3.698-3.13 ± 2.501-0.28 ± 1.646-1.65 ± 3.748
Day 211-0.37 ± 4.0651.53 ± 4.799-1.83 ± 2.0661.40 ± 1.9301.05 ± 1.768
PrimaryChange From Baseline Values in Urine Specific Gravity

Urine samples were collected for the analysis of urine specific gravity. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value. Urine specific gravity is measured as the ratio of urine density compared with water density.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Ratio of urine to water density
Change From Baseline Values in Urine Specific Gravity
Ratio of urine to water densityCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-0.0017 ± 0.007030.0033 ± 0.005850.0032 ± 0.005230.0028 ± 0.004270.0080 ± 0.00566
Day 570.0000 ± 0.008320.0059 ± 0.007630.0028 ± 0.005190.0038 ± 0.004570.0130 ± 0.00141
Day 85-0.0007 ± 0.006530.0020 ± 0.004810.0057 ± 0.004410.0013 ± 0.004500.0130 ± 0.00000
Day 211-0.0020 ± 0.008510.0024 ± 0.006840.0010 ± 0.00522-0.0005 ± 0.003870.0060 ± 0.00849
PrimaryChange From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio

Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Milligrams per millimole Creatinine
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio
Milligrams per millimole CreatinineCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Urine albumin/creatinine ratio, Day29,n=0,1,0,0,0—-3.340 ± NA———
Urine albumin/creatinine ratio, Day57,n=0,2,0,0,0—-10.580 ± 10.9743———
Urine albumin/creatinine ratio, Day85,n=0,1,1,0,0—-3.480 ± NA0.080 ± NA——
Urine protein/creatinine ratio Day29, n=5,10,4,4,20.006 ± 0.0329-0.002 ± 0.1264-0.005 ± 0.00580.065 ± 0.02380.025 ± 0.0071
Urine protein/creatinine ratio Day57, n=6,9,3,4,2-0.007 ± 0.0589-0.043 ± 0.1168-0.003 ± 0.00580.020 ± 0.00000.010 ± 0.0000
Urine protein/creatinine ratio Day85, n=6,8,4,3,2-0.003 ± 0.0554-0.050 ± 0.1042-0.005 ± 0.01290.017 ± 0.02310.000 ± 0.0141
Urine protein/creatinine ratio Day211, n=4,8,4,3,10.003 ± 0.0150-0.073 ± 0.1235-0.005 ± 0.03110.013 ± 0.02520.000 ± NA
PrimaryChange From Baseline Values in Urine Protein

Urine samples were collected for the analysis of urine protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Milligrams per deciliter
Change From Baseline Values in Urine Protein
Milligrams per deciliterCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-1.08 ± 7.5917.06 ± 5.130-0.51 ± 2.60511.13 ± 9.2883.76 ± 5.020
Day 57-2.57 ± 7.4515.62 ± 7.9102.00 ± 5.9034.48 ± 3.5025.56 ± 3.889
Day 85-2.07 ± 5.8141.45 ± 3.7472.29 ± 2.2672.48 ± 3.9544.01 ± 0.283
Day 211-2.29 ± 7.2770.90 ± 2.832-0.46 ± 2.2140.90 ± 1.6642.71 ± 3.8250
PrimaryChange From Baseline Values in Blood Coagulation Factors: Activated Partial Thromboplastin Time and Prothrombin Time

Blood samples were collected for the analysis of blood coagulation factors:activated partial thromboplastin time (aPTT) and Prothrombin Time (PT). Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211
Reported as:
Mean · Seconds
Change From Baseline Values in Blood Coagulation Factors: Activated Partial Thromboplastin Time and Prothrombin Time
SecondsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
aPTT, Day 23, n=5,11,6,4,2-2.44 ± 4.017-2.33 ± 6.460-1.63 ± 1.715-0.45 ± 1.8080.65 ± 0.778
aPTT, Day 57, n=6,12,5,4,21.23 ± 3.518-3.03 ± 5.854-0.18 ± 3.8410.13 ± 3.627-0.35 ± 1.344
aPTT, Day 85, n=0,0,0,1,0———0.00 ± NA—
aPTT, Day 211, n=5,11,6,2,21.28 ± 6.538-1.01 ± 6.3102.70 ± 3.0461.30 ± 4.3842.60 ± 3.394
PT, Day 23, n=5,11,6,4,2-0.42 ± 0.576-0.23 ± 0.7100.12 ± 0.4830.33 ± 0.5850.60 ± 0.141
PT, Day 57, n=6,12,5,4,2-0.10 ± 0.740-0.50 ± 0.6150.20 ± 0.869-0.18 ± 0.7800.40 ± 0.141
PT, Day85, n=0,0,0,1,0———-0.80 ± NA—
PT, Day211, n=5,11,6,2,2-0.84 ± 0.623-0.35 ± 0.7260.42 ± 0.7440.45 ± 0.9190.70 ± 0.283
PrimaryChange From Baseline Values in Blood Coagulation Factor: Prothrombin International Normalized Ratio

Blood samples were collected for the analysis of blood coagulation factor: Prothrombin International normalized ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211
Reported as:
Mean · Ratio
Change From Baseline Values in Blood Coagulation Factor: Prothrombin International Normalized Ratio
RatioCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 23, n=5,11,6,4,2-0.04 ± 0.055-0.04 ± 0.0670.02 ± 0.0410.03 ± 0.0960.00 ± 0.000
Day 57, n=6,12,5,4,2-0.02 ± 0.075-0.04 ± 0.0790.02 ± 0.0840.00 ± 0.0820.00 ± 0.000
Day 85, n=0,0,0,1,0———0.00 ± NA—
Day 211, n=5,11,6,2,2-0.06 ± 0.089-0.03 ± 0.0790.02 ± 0.0750.05 ± 0.0710.00 ± 0.000
PrimaryChange in Complement C3 Level at Worst Case Post Baseline Relative to Baseline

Blood samples were collected from participants to evaluate change in complement C3 level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C3 was the minimum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and up to Day 211
Reported as:
Mean · Milligram per deciliter
Change in Complement C3 Level at Worst Case Post Baseline Relative to Baseline
Milligram per deciliterCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change in Complement C3 Level at Worst Case Post Baseline Relative to Baseline-19.8 ± 11.72-22.3 ± 12.00-16.5 ± 13.81-12.4 ± 3.78-25.5 ± 16.26
PrimaryChange in Complement C5a Level at Worst Case Post Baseline Relative to Baseline

Blood samples were collected from participants to evaluate change in complement C5a level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C5a was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and up to Day 211
Reported as:
Mean · Nanogram per milliliter
Change in Complement C5a Level at Worst Case Post Baseline Relative to Baseline
Nanogram per milliliterCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change in Complement C5a Level at Worst Case Post Baseline Relative to Baseline1.552 ± 1.39673.778 ± 6.20621.303 ± 0.86712.232 ± 2.26400.800 ± 0.0000
PrimaryChange in Complement Bb Level at Worst Case Post Baseline Relative to Baseline

Blood samples were collected from participants to evaluate change in complement Bb level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement Bb was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and up to Day 211
Reported as:
Mean · Microgram per milliliter
Change in Complement Bb Level at Worst Case Post Baseline Relative to Baseline
Microgram per milliliterCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change in Complement Bb Level at Worst Case Post Baseline Relative to Baseline0.355 ± 0.11290.365 ± 0.48350.240 ± 0.35430.472 ± 0.14390.320 ± 0.3677
PrimaryNumber of Participants With Reported Pregnancy

Female participants who were not surgically sterile or post-menopausal, underwent urine beta Human chorionic gonadotropin (Beta-HCG) pregnancy test.

Time frame:
Up to Day 211
Reported as:
Count of participants · Participants
Number of Participants With Reported Pregnancy
ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Number of Participants With Reported Pregnancy00000
PrimaryChange From Baseline in Body Temperature

Body temperature was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Degrees Celsius
Change From Baseline in Body Temperature
Degrees CelsiusCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-0.05 ± 0.288-0.09 ± 0.353-0.15 ± 0.1640.08 ± 0.2500.30 ± 0.141
Day 570.03 ± 0.294-0.16 ± 0.342-0.18 ± 0.2480.48 ± 0.0960.20 ± 0.849
Day 850.05 ± 0.451-0.18 ± 0.290-0.13 ± 0.1030.10 ± 0.115-0.20 ± 0.707
Day 211-0.20 ± 0.210-0.19 ± 0.291-0.17 ± 0.2160.23 ± 0.369-0.10 ± 0.424
PrimaryChange From Baseline in Body Weight

Body weight was measured at indicated time points. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 211
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight
KilogramsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-0.48 ± 3.4060.20 ± 0.8020.52 ± 0.7860.00 ± 0.808-1.25 ± 0.636
Day 57-0.40 ± 3.992-0.10 ± 1.834-0.18 ± 1.0090.20 ± 1.214-0.25 ± 0.354
Day 211-0.15 ± 3.627-0.40 ± 2.721-0.37 ± 1.3502.00 ± 1.2121.95 ± 0.354
PrimaryChange From Baseline in Diastolic Blood Pressure and Systolic Blood Pressure

Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure and Systolic Blood Pressure
Millimeters of Mercury (mmHg)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
SBP, Day 29-6.3 ± 13.76-8.8 ± 12.05-9.2 ± 10.11-3.0 ± 6.630.5 ± 9.19
SBP, Day 573.7 ± 11.33-3.4 ± 13.98-13.2 ± 5.317.8 ± 7.93-2.0 ± 5.66
SBP, Day 853.0 ± 12.44-5.4 ± 13.45-13.7 ± 7.994.3 ± 8.586.5 ± 13.44
SBP, Day 21110.0 ± 13.49-3.6 ± 15.21-10.2 ± 5.197.3 ± 10.215.0 ± 9.90
DBP, Day 29-4.0 ± 8.65-2.2 ± 7.77-6.0 ± 5.73-5.0 ± 7.26-0.5 ± 9.19
DBP, Day 571.0 ± 8.20-0.2 ± 9.92-3.0 ± 11.060.0 ± 9.383.0 ± 4.24
DBP, Day 852.2 ± 6.710.1 ± 12.43-3.7 ± 6.65-1.8 ± 6.084.5 ± 14.85
DBP, Day 2116.8 ± 6.370.8 ± 9.88-3.8 ± 9.564.3 ± 6.958.0 ± 8.49
PrimaryChange From Baseline in Respiratory Rate

Respiratory Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Breaths/minute
Change From Baseline in Respiratory Rate
Breaths/minuteCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 290.3 ± 1.030.7 ± 0.650.3 ± 0.52-0.8 ± 2.22-2.5 ± 2.12
Day 57-0.5 ± 1.870.6 ± 0.670.2 ± 1.33-0.8 ± 2.22-2.5 ± 2.12
Day 85-0.3 ± 1.860.5 ± 0.520.2 ± 0.41-0.8 ± 2.22-3.0 ± 1.41
Day 211-0.5 ± 1.970.7 ± 0.780.0 ± 0.10-1.0 ± 2.00-3.0 ± 1.41
PrimaryChange From Baseline in Pulse Rate

Pulse Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Reported as:
Mean · Beats/minute
Change From Baseline in Pulse Rate
Beats/minuteCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29-4.7 ± 13.634.3 ± 8.141.5 ± 5.329.0 ± 6.631.0 ± 4.24
Day 57-1.5 ± 16.348.2 ± 14.336.5 ± 14.3616.0 ± 6.068.0 ± 4.24
Day 855.7 ± 19.962.3 ± 9.10-1.7 ± 7.1516.8 ± 5.323.5 ± 7.78
Day 211-0.3 ± 18.822.9 ± 8.701.8 ± 12.2216.3 ± 8.4213.0 ± 2.83
PrimaryNumber of Participants With Abnormal Findings in Physical Examination

Physical examinations included assessment of the dermatologic, cardiovascular, respiratory, gastrointestinal, and neurological systems.

Time frame:
Up to Day 211
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Findings in Physical Examination
ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Number of Participants With Abnormal Findings in Physical Examination31100
PrimaryNumber of Participants Who Received Atleast One Concomitant Medication

A concomitant medication is defined as any medication initiated after the first dose of study, or initiated prior to the first dose of study drug and continued after the first dose of study drug.

Time frame:
Up to Day 211
Reported as:
Count of participants · Participants
Number of Participants Who Received Atleast One Concomitant Medication
ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Number of Participants Who Received Atleast One Concomitant Medication48552
PrimaryChange From Baseline in Electrocardiogram Mean Ventricular Rate

Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured mean ventricular rate (VR). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113
Reported as:
Mean · Beats per minute
Change From Baseline in Electrocardiogram Mean Ventricular Rate
Beats per minuteCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Mean VR, Day1, 3 hours Post-dose, n=6,12,6,5,24.3 ± 5.055.6 ± 8.854.5 ± 4.938.2 ± 4.6010.0 ± 2.83
Mean VR, Day1, 5 hours Post-dose, n=6,12,6,5,21.8 ± 6.522.0 ± 7.934.7 ± 6.2212.6 ± 6.888.0 ± 9.90
Mean VR, Day 2, n=6,12,6,5,2-2.7 ± 10.2710.1 ± 12.930.3 ± 2.6622.8 ± 9.155.5 ± 7.78
Mean VR, Day 22, Pre-dose, n=5,12,6,4,2-3.6 ± 5.460.4 ± 8.541.0 ± 6.540.8 ± 4.86-1.0 ± 5.66
Mean VR, Day 22, 3 hours Post-dose, n=5,12,6,4,2-1.4 ± 7.375.0 ± 7.243.7 ± 5.479.3 ± 4.928.5 ± 2.12
Mean VR, Day 22, 5 hours Post-dose, n=5,12,6,4,2-1.8 ± 10.473.4 ± 6.27-0.7 ± 5.828.0 ± 6.228.0 ± 2.83
Mean VR, Day 23, n=5,12,6,4,2-2.4 ± 8.266.3 ± 3.651.3 ± 4.7610.3 ± 4.920.0 ± 4.24
Mean VR, Day 29, n=6,12,6,4,2-1.3 ± 11.602.8 ± 7.630.2 ± 4.457.3 ± 6.133.5 ± 7.78
Mean VR, Day 113, n=6,12,6,4,2-5.2 ± 9.752.5 ± 10.60-2.3 ± 6.068.3 ± 2.068.0 ± 9.90
PrimaryChange From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia Interval and QTc Corrected by Bazett's Formula

Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured QRS duration, uncorrected QT interval, QT corrected interval-Fredericia \[QTcF\] interval and QTc corrected by Bazett's formula (QTcB). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113
Reported as:
Mean · Milliseconds
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia Interval and QTc Corrected by Bazett's Formula
MillisecondsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
PR, Day 1,3 hours Post-dose, n=6,11,6,5,2-1.2 ± 8.421.8 ± 9.993.5 ± 30.840.8 ± 8.417.0 ± 1.41
PR, Day 1, 5 hours Post-dose, n=6,11,6,5,2-1.7 ± 8.641.3 ± 8.3710.8 ± 33.521.4 ± 8.38-3.0 ± 0.00
PR, Day 2, n=6,12,6,5,21.0 ± 4.650.7 ± 15.7812.2 ± 21.45-2.4 ± 8.795.5 ± 2.12
PR, Day 22, Pre-dose, n=5,12,6,4,27.0 ± 14.27-2.4 ± 11.7011.0 ± 19.84-2.8 ± 10.878.0 ± 7.07
PR, Day 22, 3 hours Post-dose, n=5,12,6,4,22.0 ± 7.210.3 ± 14.519.2 ± 21.51-6.5 ± 11.797.5 ± 6.36
PR, Day 22, 5 hours Post-dose, n=5,11,6,4,2-0.2 ± 10.03-2.3 ± 14.189.0 ± 22.82-7.0 ± 9.425.5 ± 4.95
PR, Day 23, n=5,11,6,4,29.4 ± 12.03-1.6 ± 11.0911.2 ± 21.77-1.0 ± 7.794.5 ± 3.54
PR, Day 29, n=6,12,6,4,24.8 ± 7.28-1.7 ± 11.677.3 ± 17.64-1.8 ± 4.7210.0 ± 4.24
PR, Day 113, n=6,12,6,4,27.7 ± 8.82-1.6 ± 14.4814.3 ± 21.81-2.0 ± 8.836.0 ± 7.07
QRS duration, Day1, 3 hours Post-dose,n=6,12,6,5,20.8 ± 3.97-0.2 ± 5.082.2 ± 4.311.0 ± 2.00-1.5 ± 3.54
QRS duration, Day1, 5 hours Post-dose,n=6,12,6,5,2-0.8 ± 2.04-1.7 ± 4.386.0 ± 4.980.4 ± 1.95-3.0 ± 4.24
QRS duration, Day 2, n=6,12,6,5,20.5 ± 3.940.8 ± 3.983.7 ± 8.07-2.2 ± 4.87-0.5 ± 0.71
QRS duration, Day 22, Pre-dose, n=5,12,6,4,20.2 ± 3.11-3.6 ± 5.074.2 ± 3.19-0.8 ± 4.79-4.0 ± 2.83
QRS duration, Day 22, 3 hours Post-dose, n=5,12,6,4,21.6 ± 3.51-1.2 ± 4.115.0 ± 6.992.5 ± 1.91-1.0 ± 0.00
QRS duration, Day 22, 5 hours Post-dose, n=5,12,6,4,21.0 ± 5.15-1.0 ± 3.866.3 ± 5.28-0.3 ± 5.12-2.0 ± 1.41
QRS duration, Day 23, n=5,12,6,4,2-0.4 ± 5.370.9 ± 3.090.3 ± 7.00-0.5 ± 4.121.5 ± 3.54
QRS duration, Day 29, n=6,12,6,4,20.3 ± 4.180.7 ± 4.915.5 ± 7.503.0 ± 6.980.5 ± 0.71
QRS duration, Day 113, n=6,12,6,4,20.3 ± 5.720.0 ± 4.904.7 ± 8.09-2.8 ± 5.191.0 ± 1.41
QT, Day 1, 3 hours Post-dose, n=6,12,6,5,2-11.8 ± 14.85-12.4 ± 17.30-5.7 ± 8.21-23.8 ± 9.55-20.5 ± 0.71
QT, Day 1, 5 hours Post-dose, n=6,12,6,5,2-11.3 ± 19.41-10.3 ± 18.25-7.3 ± 12.80-37.6 ± 19.89-21.0 ± 11.31
QT, Day 2, n=6,12,6,5,2-0.3 ± 29.34-25.5 ± 29.570.3 ± 6.41-62.8 ± 19.3819.5 ± 19.09
QT, Day 22, Pre-dose, n=5,12,6,4,215.2 ± 12.911.9 ± 17.052.0 ± 19.65-1.0 ± 12.683.0 ± 11.31
QT, Day 22, 3 hours Post-dose, n=5,12,6,4,211.2 ± 30.60-8.7 ± 21.05-3.0 ± 17.31-27.3 ± 22.47-16.0 ± 12.73
QT, Day 22, 5 hours Post-dose, n=5,12,6,4,25.8 ± 29.71-8.0 ± 18.682.5 ± 16.31-25.3 ± 23.73-17.5 ± 9.19
QT, Day 23, n=5,12,6,4,28.0 ± 23.63-13.9 ± 13.81-5.2 ± 16.74-30.5 ± 18.81-8.5 ± 6.36
QT, Day 29, n=6,12,6,4,29.0 ± 31.92-5.4 ± 20.972.5 ± 15.45-23.0 ± 16.02-4.0 ± 31.11
QT, Day 113, n=6,12,6,4,213.7 ± 30.59-15.4 ± 49.824.2 ± 17.95-28.3 ± 13.33-20.0 ± 22.63
QTcB, Day 1,3 hours Post-dose, n=1,3,2,0,05.0 ± NA3.3 ± 3.063.0 ± 1.41——
QTcB, Day 1, 5 hours Post-dose, n=1,3,2,0,0-9.0 ± NA-1.3 ± 11.024.5 ± 0.71——
QTcB, Day 2, n=1,3,2,0,0-3.0 ± NA4.3 ± 7.572.5 ± 0.71——
QTcB, Day 22, Pre-dose, n=1,3,2,0,027.0 ± NA7.3 ± 6.43-0.5 ± 7.78——
QTcB, Day 22, 3 hours Post-dose, n=1,3,2,0,016.0 ± NA18.7 ± 16.77-2.0 ± 2.83——
QTcB, Day 22, 5 hours Post-dose, n=1,3,2,0,011.0 ± NA3.7 ± 2.31-14.5 ± 6.36——
QTcB, Day 23, n=1,3,2,0,014.0 ± NA7.3 ± 8.62-3.5 ± 7.78——
QTcB, Day 29, n=1,4,2,0,021.0 ± NA3.0 ± 8.986.5 ± 6.36——
QTcB, Day 113, n=1,5,3,0,05.0 ± NA-1.8 ± 3.27-13.0 ± 8.54——
QTcF, Day 1,3 hours Post-dose, n=5,9,4,5,2-6.0 ± 6.28-1.9 ± 8.163.5 ± 7.05-3.8 ± 13.88-4.5 ± 4.95
QTcF, Day 1,5 hours Post-dose, n=5,9,4,5,2-9.6 ± 10.67-8.9 ± 8.491.3 ± 5.32-9.0 ± 13.84-7.5 ± 6.36
QTcF, Day 2, n=4,8,4,5,2-8.6 ± 13.50-12.5 ± 9.01-1.0 ± 4.69-44.6 ± 65.50-11.0 ± 5.66
QTcF, Day 22, Pre-dose, n=5,9,4,4,2-1.0 ± 2.940.7 ± 12.198.8 ± 8.881.3 ± 3.77-1.5 ± 2.12
QTcF, Day 22, 3 hours Post-dose, n=4,9,4,4,20.8 ± 10.08-1.0 ± 11.109.5 ± 10.47-4.5 ± 13.48-1.5 ± 10.61
QTcF, Day 22, 5 hours Post-dose, n=4,9,4,5,2-5.0 ± 7.66-3.6 ± 12.975.8 ± 9.95-5.8 ± 12.55-4.5 ± 4.95
QTcF, Day 23, n=4,8,4,4,2-0.8 ± 8.38-3.3 ± 9.82-0.5 ± 7.05-5.0 ± 9.20-10.0 ± 0.00
QTcF, Day 29, n=5,8,4,4,24.0 ± 22.55-0.1 ± 9.603.0 ± 8.98-5.5 ± 10.08-4.5 ± 10.61
QTcF, Day 113, n=5,6,3,4,2-1.08 ± 20.24-1.0 ± 14.094.0 ± 12.29-6.5 ± 10.75-7.0 ± 5.66
SecondaryChange From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29

Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The last observation carried forward (LOCF) method was used to impute missing values at Day 29 in this analysis.

Time frame:
Baseline (Day 1 pre-dose) and Day 29
Reported as:
Mean · Log10 (International Units/milliliter)
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29
Log10 (International Units/milliliter)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29-0.384 ± 0.4199-1.655 ± 1.4791-0.001 ± 0.47100.075 ± 0.16670.000 ± 0.0000
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.116 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = <0.001 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 4 GSK3228836 300 mg vs Cohort 4 Placebo · ANCOVA · p = 0.573 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryChange From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31

Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Week 31
Reported as:
Mean · Log10 (International Units/milliliter)
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31
Log10 (International Units/milliliter)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31-4.754 ± 0.8344-4.770 ± 1.2823-3.547 ± 1.27980.000 ± 0.00000.000 ± NA
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.609 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.141 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryChange From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29

Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The LOCF method was used to impute missing values at Day 29 in this analysis.

Time frame:
Baseline (Day 1 pre-dose) and Day 29
Reported as:
Mean · Log10 (International Units/milliliter)
Change From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29
Log10 (International Units/milliliter)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29-0.504 ± 0.5656-1.556 ± 1.37870.000 ± 0.1116-1.986 ± 1.7986-0.008 ± 0.0390
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.245
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.001 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 4 GSK3228836 300 mg vs Cohort 4 Placebo · ANCOVA · p = 0.762 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryChange From Baseline in HBsAg Level in Serum at Week 31

Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1 pre-dose) and Week 31
Reported as:
Mean · Log10 (International Units/milliliter)
Change From Baseline in HBsAg Level in Serum at Week 31
Log10 (International Units/milliliter)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in HBsAg Level in Serum at Week 31-0.523 ± 0.9299-0.547 ± 0.61090.059 ± 0.3859-1.519 ± 1.4821-0.043 ± 0.0178
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.141 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.081 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 4 GSK3228836 300 mg vs Cohort 4 Placebo · ANCOVA · p = 0.616 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryPercentage of Participants Who Achieved HBsAg Loss at Day 29 and Week 31

Blood samples were collected to evaluate the percentage of participants with HBsAg loss at Day 29 and Week 31. A 'Loss' of HBsAg means antigen is negative. HBsAg Loss percentage is defined as number of participants with HBsAg loss divided by total number of participants assessed multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug.

Time frame:
At Day 29 and Week 31
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HBsAg Loss at Day 29 and Week 31
Percentage of ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29016.7020.00
Week 3100000
SecondaryPercentage of Participants Who Achieved HBV e Antigen (HBeAg) Loss at Day 29 and Week 31 Who Were HBeAg Positive at Baseline

Blood samples were collected to evaluate the percentage of participants with HBeAg loss at Day 29 and Week 31. A 'Loss' of HBeAg means antigen is negative. HBeAg Loss percentage is defined as number of participants with HBeAg loss divided by number of participants with positive HBeAg at Baseline multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug. Participants was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.

Time frame:
Baseline (Day 1, Pre dose) and at Day 29 and Week 31
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HBV e Antigen (HBeAg) Loss at Day 29 and Week 31 Who Were HBeAg Positive at Baseline
Percentage of ParticipantsCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Day 29000——
Week 31000——
SecondaryChange From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline

Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 International Units/milliliter (IU/mL).

Time frame:
Baseline (Day 1, Pre dose) and at Day 29
Reported as:
Mean · Log10 (IU/mL)
Change From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline
Log10 (IU/mL)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline-0.004 ± 0.3967-0.052 ± 0.67410.133 ± 0.2884——
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.763 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.804 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryChange From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline

Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.

Time frame:
Baseline (Day 1, Pre dose) and Week 31
Reported as:
Mean · Log10 IU/mL
Change From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline
Log10 IU/mLCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Change From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline-0.577 ± 1.3711-0.195 ± 0.50470.131 ± 0.7477——
Statistical analysis
  • Cohort 1 GSK3228836 150 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.372 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
  • Cohort 2 and Cohort 3 GSK3228836 300 mg vs Cohorts 1-3 Placebo · ANCOVA · p = 0.954 (Baseline was the covariate and treatment group as a factor for the comparison between GSK3228836 and placebo group)
SecondaryPlasma Concentrations of GSK3228836 in Participants With Chronic HBV Infection

Plasma samples were collected from participants with chronic HBV infection at indicated time points for pharmacokinetic analysis of GSK3228836.

Time frame:
Day 1:pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, Days 2 and 23: 24 hours post-dose, Day 4: 72 hours post-dose, Days 8 and 15: pre-dose, Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, and Days 29, 36, 57, 85, 113, and 211
Reported as:
Mean · Nanogram per milliliter
Plasma Concentrations of GSK3228836 in Participants With Chronic HBV Infection
Nanogram per milliliterCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohort 4 GSK3228836 300 mg
Day 1, pre-dose, n=6,12,50.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
Day 1, 0.5 hour post-dose, n=6,12,51187.00 ± 1052.2562145.58 ± 1295.5331630.00 ± 539.583
Day 1, 1 hour post-dose, n=6,11,51909.33 ± 1287.3834950.91 ± 2025.3024074.00 ± 1314.565
Day 1, 1.5 hours post-dose, n=6,12,52440.00 ± 1515.8236536.67 ± 2710.7046100.00 ± 1816.631
Day 1, 2 hours post-dose, n=6,12,52976.67 ± 1444.7938387.50 ± 3287.9817556.00 ± 2672.579
Day 1, 3 hours post-dose, n=6,12,53360.00 ± 1614.9559905.00 ± 3494.3088916.00 ± 2541.324
Day 1, 4 hours post-dose, n=6,12,53340.00 ± 1223.7819658.33 ± 3612.1899632.00 ± 2115.401
Day 1, 5 hours post-dose, n=6,12,53210.00 ± 1156.9629813.33 ± 3524.3769122.00 ± 2616.662
Day 1, 6 hours post-dose, n=6,12,52933.33 ± 986.0979345.00 ± 3258.8638580.00 ± 2203.418
Day 2, 24 hours post dose, n=6,12,5112.22 ± 79.406336.88 ± 301.302356.00 ± 140.490
Day 4 , 72 hours post-dose, n=6,12,56.77 ± 2.75912.92 ± 3.97515.24 ± 3.138
Day 8, pre-dose, n=6,12,47.69 ± 4.54022.07 ± 7.71521.80 ± 6.458
Day 15, pre-dose, n=6,12,410.90 ± 4.98930.29 ± 12.59833.33 ± 11.536
Day 22, pre-dose, n=5,12,49.38 ± 2.27922.85 ± 9.84825.43 ± 7.630
Day 22 0.5 hour pre-dose, n=5,12,41315.40 ± 1064.3802073.58 ± 883.8061447.75 ± 850.592
Day 22, 1 hour post-dose, n=5,12,42133.00 ± 1616.7384815.83 ± 1835.5953477.50 ± 2009.766
Day 22, 1.5 hours post-dose, n=5,12,42874.00 ± 1872.1737094.17 ± 2862.1785235.00 ± 3036.341
Day 22, 2 hours post-dose, n=5,12,43466.00 ± 2033.1588351.67 ± 3274.5966765.00 ± 3805.422
Day 22, 3 hours post-dose, n=5,12,44070.00 ± 2146.7429137.50 ± 3303.1398325.00 ± 5007.950
Day 22, 4 hours post-dose, n=5,12,43760.00 ± 1572.2608650.00 ± 2913.3398690.00 ± 4808.791
Day 22, 5 hours post-dose, n=5,12,43566.00 ± 1229.5048072.50 ± 2748.3228027.50 ± 4274.166
Day 22, 6 hours post-dose, n=5,12,42990.00 ± 817.0997769.17 ± 2295.6977447.50 ± 3817.376
Day 23, 24 hours post-dose, n=5,12,4152.90 ± 148.879387.88 ± 209.944524.00 ± 372.305
Day 29, n=5,12,48.88 ± 1.68023.42 ± 9.35821.50 ± 4.883
Day 36, n=5,12,45.32 ± 1.09812.58 ± 6.3328.96 ± 3.246
Day 57, n=5,12,41.91 ± 0.4053.80 ± 1.2941.90 ± 0.752
Day 85, n=5,12,40.00 ± 0.001.32 ± 0.8720.31 ± 0.625
Day 133, n=5,12,40.91 ± 1.2730.59 ± 0.6190.00 ± 0.00
Day 211, n=5,12,40.38 ± 0.8451.04 ± 2.4380.37 ± 0.730

Adverse events

Collected over Non-serious (>=5%) and serious adverse events were collected up to Day 211. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 GSK3228836 150 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 2 and Cohort 3 GSK3228836 300 mg0/12 (0%)1/12 (8.3%)6/12 (50%)
Cohorts 1-3 Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Cohort 4 GSK3228836 300 mg0/5 (0%)0/5 (0%)3/5 (60%)
Cohort 4 Placebo0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Alanine aminotransferase increasedInvestigations0/61/120/60/50/2
Most frequent other events
Showing 10 of 23
Most frequent other events
EventCohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 Placebo
Injection site pruritusGeneral disorders2/61/120/60/50/2
Injection site erythemaGeneral disorders0/63/120/61/50/2
PyrexiaGeneral disorders1/63/121/61/50/2
Injection site bruisingGeneral disorders1/60/120/61/50/2
Injection site swellingGeneral disorders0/62/120/61/50/2
Injection site painGeneral disorders1/61/120/60/50/2
Injection site rashGeneral disorders1/60/120/60/50/2
Abdominal discomfortGastrointestinal disorders1/60/120/60/50/2
Mouth swellingGastrointestinal disorders1/60/120/60/50/2
NauseaGastrointestinal disorders1/62/121/60/50/2

Baseline characteristics

In Cohort 3 participants were administered GSK3228836 300 mg instead of 450 mg as per sponsor's decision, hence Cohort 2 and Cohort 3 have been combined.

Age, Continuous
Age, Continuous(Years)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 PlaceboTotal
Mean42.5 ± 11.2242.6 ± 14.1249.3 ± 12.6648.4 ± 7.4037.0 ± 2.8344.5 ± 11.90
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 PlaceboTotal
Female3821115
Male3444116
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 GSK3228836 150 mgCohort 2 and Cohort 3 GSK3228836 300 mgCohorts 1-3 PlaceboCohort 4 GSK3228836 300 mgCohort 4 PlaceboTotal
Race — Asian61265231
08

Study locations

7 sites
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Korea University Ansan Hospital
    Ansan, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busan, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
  • Pusan National University Hospital
    Pusan, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
09

References and documents

Publications

  • Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12. PubMed 34642494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Dec 2019, 33 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's 33 months is close to that.

Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 5, 2016
StartActual
Feb 24, 2017
Primary completionActual
Dec 18, 2019
CompletionActual
Dec 26, 2019
Results first posted
Dec 21, 2020
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02981602
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Feb 24, 2017
Primary completion
Dec 18, 2019
Completion
Dec 26, 2019
Results posted
Dec 21, 2020
Last update
Aug 10, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion